What's in Hanlim Pharm. Co., Ltd.'s pipeline?

Hanlim Pharm. Co., Ltd. has 25 drugs in our index: 3 marketed, 0 filed, 14 in Phase 3, 2 in Phase 2, 6 in Phase 1.

Which companies overlap with Hanlim Pharm. Co., Ltd.'s portfolio?

Top competitors by shared drug class: Merck Sharp & Dohme LLC, Sanofi, Hanmi Pharmaceutical Company Limited, AstraZeneca, EMS.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/hanlim-pharm-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Hanlim Pharm. Co., Ltd. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hanlim Pharm. Co., Ltd. pipeline: 3 marketed, 0 filed, 14 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 14 Phase 3 2 Phase 2 6 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Venitol Tab.	Venitol Tab.	marketed	Venotropic agent		Cardiovascular
Risedronate/Cholecalciferol combination	Risedronate/Cholecalciferol combination	marketed	Bisphosphonate + vitamin D3 combination	Osteoclast farnesyl pyrophosphate synthase (risedronate); vitamin D receptor (cholecalciferol)	Bone metabolism / Osteoporosis
Placebo of Venitol Tab.	Placebo of Venitol Tab.	marketed
Umkamin(Active Comparator)	Umkamin(Active Comparator)	phase 3	GLP-1 receptor agonist	GLP-1R	Diabetes
HL140 10/10	HL140 10/10	phase 3
Charcotrace Inj.	Charcotrace Inj.	phase 3			Neurology / Diagnostic Imaging
risedronate combine	risedronate combine	phase 3	Bisphosphonate	Hydroxyapatite	Osteoporosis
Placebo(for Risedronate)	Placebo(for Risedronate)	phase 3
Talion Tab	Talion Tab	phase 3	SGLT2 inhibitor	SGLT2	Diabetes
HL140 5/10	HL140 5/10	phase 3	PD-1/PD-L1 inhibitor	PD-1	Oncology
mometasone furoate plus azelastine HCl	mometasone furoate plus azelastine HCl	phase 3	Corticosteroid and antihistamine combination	Histamine receptors (H1)	Ophthalmology
HL140 20/10	HL140 20/10	phase 3

Therapeutic area mix

Cardiovascular · 4
Oncology · 2
Diabetes · 2
Osteoporosis · 1
Neurology / Diagnostic Imaging · 1
Bone metabolism / Osteoporosis · 1
Ophthalmology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Merck Sharp & Dohme LLC · 5 shared drug classes
Sanofi · 4 shared drug classes
Hanmi Pharmaceutical Company Limited · 3 shared drug classes
AstraZeneca · 3 shared drug classes
EMS · 3 shared drug classes
Hoffmann-La Roche · 3 shared drug classes
GlaxoSmithKline · 3 shared drug classes
HK inno.N Corporation · 3 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Hanlim Pharm. Co., Ltd.:

Cite this brief

Drug Landscape (2026). Hanlim Pharm. Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/hanlim-pharm-co-ltd. Accessed 2026-06-10.